[Abstract] Dipeptidyl peptidase-4(DPP-4)inhibitors is a new kind oral anti-diabetic medicine, with good glucose lowering effect, as well as low risk of hypoglycemia, no weight gain, easy to use. In addition, it is with cardiovascular protection which beyond glucose lowering, such as: anti-hypertension, lipids lowering, anti-inflammation, anti-atherosclerosis, improving cardiac function etc. Previous retrospective studies demonstrated that DPP-4 inhibitors can reduce cardiovascular risks, but with the limitations of the study design, the evidence is not powerful enough. Since the FDA released new requirement for new anti-diabetic drug in 2008, many prospective clinical trials which using cardiovascular events as primary endpoint has been launched. SAVOR study and EXAMINE study are first to release the results, bothdemonstrated that saxagliptin and alogliptin do not increase CV risks.But an unexpected signal came out, that is increasing hospitalization for heart failure which needs continuous attention. More study results will be release later in future, including TECOS of sitagliptin and CAROLINA of linagliptin, hope they can be robust clinical evidence for the treatment choice of T2DM with CVD and high CV risk patients.
[Key words]Dipeptidyl peptidase-4(DPP-4)inhibitors; Diabetes mellitus, type 2;Cardiovascular diseases;Drug evaluation